Patents by Inventor Eric A. Tanifum
Eric A. Tanifum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165273Abstract: Embodiments of the present disclosure pertain to a composition with molecules that self-assemble to form a particle. Additional embodiments of the present disclosure pertain to methods of imaging a region of a subject by: (1) administering the compositions of the present disclosure to the subject to result in the accumulation of the molecules in the region of the subject; and (2) imaging the region of the subject. In some embodiments, the imaged region includes a tumor. In some embodiments, the imaged region includes a blood vessel.Type: ApplicationFiled: October 31, 2023Publication date: May 23, 2024Applicants: Baylor College of Medicine, Texas Children’s HospitalInventors: Eric Tanifum, Ananth Annapragada, Xianwei Sun
-
Publication number: 20230398238Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 24, 2023Publication date: December 14, 2023Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Patent number: 11779664Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 5, 2022Date of Patent: October 10, 2023Assignees: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Publication number: 20230136718Abstract: Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.Type: ApplicationFiled: November 14, 2022Publication date: May 4, 2023Applicant: Alzeca Biosciences, LLCInventors: Ananth V. Annapragada, Peter Nilsson, Carlo Medici, Eric A. Tanifum
-
Publication number: 20220265868Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 5, 2022Publication date: August 25, 2022Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Patent number: 11312685Abstract: Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.Type: GrantFiled: April 27, 2018Date of Patent: April 26, 2022Assignees: Texas Heart Institute, Texas Children's HospitalInventors: Darren Woodside, Peter Vanderslice, Robert Market, Ronald Biediger, Richard Dixon, James T. Willerson, Ananth Annapragada, Eric Tanifum
-
Patent number: 11241510Abstract: Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19F molecular species and to generate probes with distinct 19F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.Type: GrantFiled: November 30, 2017Date of Patent: February 8, 2022Assignee: TEXAS CHILDREN'S HOSPITALInventors: Ananth Annapragada, Eric A. Tanifum
-
Publication number: 20220023445Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: August 16, 2021Publication date: January 27, 2022Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Patent number: 11141495Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: GrantFiled: February 14, 2020Date of Patent: October 12, 2021Assignee: Texas Children's HospitalInventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Patent number: 11116854Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: GrantFiled: January 29, 2021Date of Patent: September 14, 2021Assignee: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Publication number: 20210252170Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 12, 2021Publication date: August 19, 2021Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Publication number: 20210236662Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Patent number: 11052162Abstract: The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.Type: GrantFiled: September 15, 2017Date of Patent: July 6, 2021Assignee: TEXAS CHILDREN'S HOSPITALInventors: Ananth Annapragada, Anil Shetty, Ketankumar B Ghaghada, Eric Tanifum
-
Publication number: 20210188774Abstract: Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.Type: ApplicationFiled: April 27, 2018Publication date: June 24, 2021Inventors: Darren Woodside, Peter Vanderslice, Robert Market, Ronald Biediger, Richard Dixon, James T. Willerson, Ananth Annapragada, Eric Tanifum
-
Publication number: 20210170055Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: January 29, 2021Publication date: June 10, 2021Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Publication number: 20200261605Abstract: Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.Type: ApplicationFiled: January 24, 2020Publication date: August 20, 2020Inventors: Ananth V. ANNAPRAGADA, Peter NILSSON, Carlo MEDICI, Eric A. TANIFUM
-
Publication number: 20200179540Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Publication number: 20200069820Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: November 8, 2019Publication date: March 5, 2020Inventors: Ananth Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Patent number: 10537649Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: GrantFiled: December 1, 2016Date of Patent: January 21, 2020Assignee: TEXAS CHILDREN'S HOSPITALInventors: Ananth Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Publication number: 20190255196Abstract: The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Inventors: Ananth ANNAPRAGADA, Anil SHETTY, Ketankumar B GHAGHADA, Zbigniew A STAROSOLSKI, Eric TANIFUM